Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00641732 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement
A Phase 2 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 2
- Development phase
- 1,045
- Enrollment target
NCT00641732: Completed Phase 2 study, sponsored by Takeda.
NCT00641732 is a Phase 2 study that has completed, run by Takeda. The registered enrollment target is 1,045 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (686% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00641732, a Phase 2 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 1,045 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if TAK-442, once daily (QD) or twice daily (BID), is as safe and effective as enoxaparin in preventing the development of blood clots after knee replacement surgery.
Interventions
- DRUG TAK-442
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,045 participants |
| Start Date | 2007-10 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
What the finished NCT00641732 record still lists
NCT00641732 is an interventional study that assigns participants to a tested intervention. Its 1,045 participants enrollment target places it among the larger protocols in the corpus, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (686% higher).
The record links to 0 conditions, and to 1 intervention - of which TAK-442 is the first listed.
NCT00641732 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00641732 about?
NCT00641732 is a clinical study titled "Efficacy and Safety of TAK-442 in Subjects Undergoing Total Knee Replacement". The purpose of this study is to determine if TAK-442, once daily (QD) or twice daily (BID), is as safe and effective as enoxaparin in preventing the development of blood clots after knee replacement surgery.
What is the current status of trial NCT00641732?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 1,045 participants. The study started on 2007-10. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00641732?
The interventions under investigation include: TAK-442 (DRUG).
Who is sponsoring clinical trial NCT00641732?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00641732's enrollment target sits among peer trials
1,045 25th of 2000 higher than 1,976 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06717347 · 1,046 participants · Phase 3
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- NCT04685616 · 1,042 participants · Phase 3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
- NCT04505618 · 1,050 participants · NA
Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease
- NCT04511806 · 1,050 participants
Childhood Cancer Predisposition Study (CCPS)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia